296 related articles for article (PubMed ID: 18930517)
21. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
Sittiwangkul R; Pongprot Y; Silvilairat S; Phornphutkul C
Singapore Med J; 2006 Sep; 47(9):780-4. PubMed ID: 16924360
[TBL] [Abstract][Full Text] [Related]
22. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease.
Wang CL; Wu YT; Lee CJ; Liu HC; Huang LT; Yang KD
J Pediatr; 2002 Oct; 141(4):560-5. PubMed ID: 12378198
[TBL] [Abstract][Full Text] [Related]
23. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
Kobayashi T; Inoue Y; Takeuchi K; Okada Y; Tamura K; Tomomasa T; Kobayashi T; Morikawa A
Circulation; 2006 Jun; 113(22):2606-12. PubMed ID: 16735679
[TBL] [Abstract][Full Text] [Related]
24. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
Tsai MH; Huang YC; Yen MH; Li CC; Chiu CH; Lin PY; Lin TY; Chang LY
J Pediatr; 2006 Jan; 148(1):38-43. PubMed ID: 16423595
[TBL] [Abstract][Full Text] [Related]
25. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
26. Platelet vascular endothelial growth factor is a useful predictor for prognosis in Kawasaki syndrome.
Ueno K; Nomura Y; Hashiguchi T; Masuda K; Morita Y; Hazeki D; Eguchi T; Maruyama I; Kawano Y
Br J Haematol; 2010 Jan; 148(2):285-92. PubMed ID: 19793253
[TBL] [Abstract][Full Text] [Related]
27. A Comprehensive Assessment of the Value of Laboratory Indices in Diagnosing Kawasaki Disease.
Ye Q; Shao WX; Shang SQ; Zhang T; Hu J; Zhang CC
Arthritis Rheumatol; 2015 Jul; 67(7):1943-50. PubMed ID: 25778686
[TBL] [Abstract][Full Text] [Related]
28. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[TBL] [Abstract][Full Text] [Related]
29. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S; Kawashima H; Kashiwagi Y; Hoshika A
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[TBL] [Abstract][Full Text] [Related]
31. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease.
Hirono K; Foell D; Xing Y; Miyagawa-Tomita S; Ye F; Ahlmann M; Vogl T; Futatani T; Rui C; Yu X; Watanabe K; Wanatabe S; Tsubata S; Uese K; Hashimoto I; Ichida F; Nakazawa M; Roth J; Miyawaki T
J Am Coll Cardiol; 2006 Sep; 48(6):1257-64. PubMed ID: 16979015
[TBL] [Abstract][Full Text] [Related]
32. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease.
Doi M; Takeda T; Sakurai Y; Kato J; Hayashi T; Fukuda K; Takase T; Shima M
J Investig Allergol Clin Immunol; 2010; 20(5):413-8. PubMed ID: 20945608
[TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
[TBL] [Abstract][Full Text] [Related]
34. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of the serum proteome in Kawasaki disease patients before and after immunoglobulin therapy.
Zhang L; Jia HL; Huang WM; Liu CW; Hua L; Liu TC; Mao LJ; Xu YF; Li W; Xia SL; Gan YY; Deng L; Zhang G
Biochem Biophys Res Commun; 2014 Apr; 447(1):19-25. PubMed ID: 24690176
[TBL] [Abstract][Full Text] [Related]
36. Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease.
Kobayashi T; Kimura H; Okada Y; Inoue Y; Kobayashi T; Shinohara M; Morikawa A
Clin Exp Immunol; 2007 Apr; 148(1):112-8. PubMed ID: 17286760
[TBL] [Abstract][Full Text] [Related]
37. An elevated value on drug-induced lymphocyte stimulation test for immunoglobulin is an immunological abnormality of Kawasaki disease.
Nomura Y; Masuda K; Eguchi T; Morita Y; Ueno K; Kawano Y
Int Arch Allergy Immunol; 2010; 153(1):102-6. PubMed ID: 20357491
[TBL] [Abstract][Full Text] [Related]
38. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
Liu F; Ding Y; Yin W
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec; 15(12):1109-12. PubMed ID: 24342209
[TBL] [Abstract][Full Text] [Related]
39. [Development of diagnosis].
Ogata S; Ishii M
Nihon Rinsho; 2008 Feb; 66(2):301-6. PubMed ID: 18260329
[TBL] [Abstract][Full Text] [Related]
40. Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000).
Lee KY; Han JW; Lee HS; Hong JH; Hahn SH; Lee JS; Whang KT
Pediatr Infect Dis J; 2004 Jan; 23(1):52-5. PubMed ID: 14743047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
